Figure 6.

Cellular effects of FYLIR peptide agent. A, GET-FYLIR has cytoplasmic, nuclear, and nucleolar localization. HeLa cells were treated with GET-FYLIR (10 μm) for 24 h and assessed by confocal microscopy (nuclei were counterstained with Hoechst 33342). The white scale bar is 20 μm. B, GET-FYLIR decreases cell viability cell type–specifically and dose-dependently. Cell viability (Presto Blue assay) was assessed after 24 h of incubation with GET-FYLIR (0, 10, 20, and 50 μm) in KNS-42, U87, BJ6, HeLa, NIH3T3, MCF7, and Panc1 cells. Cell viability was expressed as percentage of cell viability ± S.D. (n = 3 biological repeats). C, GET-FYLIR induces S phase arrest cell type–specifically. Cell cycle analysis was conducted using NIH3T3 cells (n = 5 biological repeats) and Panc1 cells (n = 7 biological repeats) untreated or incubated with GET-FYLIR (20 μm) for 24 h. Cells were fixed, stained with propidium iodide staining solution, and analyzed for DNA content. The distribution and percentage of cells in subG₀, G₀, S, G₂, and super-G₂ phase of the cell cycle are indicated.